Equipment and Services Health Care Equipment and Supplies

  • Edwards earned 76 cents a share, excluding one-time items, in the second quarter. Analysts on average had expected 70 cents a share, according to Thomson Reuters I/B/E/S. The Irvine, California- based medical device maker raised its full-year forecast, excluding items, by 11 cents, to a range of $2.78 to $2.88 a share.

  • July 21- Theranos Inc hired two executives to oversee regulatory, quality and compliance standards, in a bid to turn around the struggling blood-testing company after it received sanctions from U.S. regulators. He will work on getting FDA clearances and approvals, marketing new products, and look into medical-device quality systems. The company, once valued at...

  • July 19- Two former executives of Acclarent Inc, a medical device company bought by Johnson& Johnson in 2010, were convicted on Wednesday by a U.S. jury on charges of promoting a product for an unapproved use. Former Acclarent Chief Executive William Facteau and former Vice President of Sales Patrick Fabian were found guilty in federal court in Boston of 10...

  • July 19- Two former executives of Acclarent Inc, a medical device company bought by Johnson& Johnson in 2010, were convicted on Wednesday by a U.S. jury on charges of promoting a product for an unapproved use. Former Acclarent Chief Executive William Facteau and former Vice President of Sales Patrick Fabian were found guilty in federal court in Boston of 10...

  • *Results affected by Venezuela operations. July 20- Abbott Laboratories reported better-than-expected quarterly sales and profit as strong sales in its medical device business more than made up for the hit from an economic turmoil in Venezuela. Abbott is one of the major U.S. companies to be affected by troubled operations in Venezuela.

  • *Results affected by Venezuela operations. July 20- Abbott Laboratories reported better-than-expected quarterly sales and profit as strong sales in its medical device business more than made up for the hit from an economic turmoil in Venezuela. Abbott, which has four core divisions- nutrition, diagnostics, medical devices and branded generic...

  • Sales in the medical device division rose 6.4 percent to $1.37 billion in the second quarter, driven primarily by better sales of products such as MitraClip that repairs heart valves less invasively. The company, which rakes in two-thirds of its revenue from outside the United States, said results in emerging markets were weighed down by political turmoil in...

  • July 20- Abbott Laboratories reported a 3.2 percent rise in quarterly sales, helped by strength in its branded generics and medical device businesses. Net earnings from continuing operations were $812 million, or 40 cents per share, in the second quarter ended June 30, compared with $786 million, or 52 cents per share, a year earlier. The company's net sales rose to...

  • It said instrument and accessory revenue rose 14 percent as procedures using da Vincis climbed 16 percent, driven by growth in U.S. general surgeries, such as hernia repairs, and by growth in urological procedures, such as prostate surgeries, outside the United States. Procedures rose 25 percent outside the United States, helped by growth in Japan, China and South...

  • J&J, which is the first major U.S. drugmaker to announce quarterly earnings, raised its 2016 sales forecast to a range of $71.5 billion to $72.2 billion, from $71.2 billion to $71.9 billion previously estimated. The maker of medical devices, drugs and personal care products also increased its adjusted profit range to $6.63- $6.73 per share, from $6.53- $6.68 per...

  • NEW YORK, July 8- Shares of many U.S. companies that produce prescription medicines have been under pressure this year, but the picture has been rosier for makers of pacemakers, knee replacements and other medical devices. While biotechnology and specialty pharmaceutical companies endure scrutiny over drug costs, medical device companies have avoided that...

  • June 30- Medical device maker NuVasive Inc will pay rival Medtronic Plc $45 million to settle a longstanding patent fight related to spinal surgery technology, NuVasive said on Thursday. The patent fight included a couple of rounds at a federal appeals court and a brief trip to the U.S. Supreme Court. It began when Warsaw Orthopedic Inc, a subsidiary of Dublin-...

  • Cleveland Clinic CEO: We still haven't tested Theranos tech

    Embattled Theranos still has not taken advantage of the Cleveland Clinic's offer to test the Silicon Valley startup's new blood diagnostic technology, says Dr. Toby Cosgrove.

  • Reigning in health costs: Cleveland Clinic CEO

    Dr. Toby Cosgrove, Cleveland Clinic CEO, shares his thoughts on replacing Obamacare and containing the high cost of health care.

  • Cleveland Clinic CEO on Zika threat

    Dr. Toby Cosgrove, Cleveland Clinic CEO talks about the threat of the Zika virus, how the CDC is handling the spread of the virus, and those most at risk ahead of this summer's Olympics.

  • A woman walks past the IBM logo

    IBM Watson Health has unveiled a new partnership with the Department of Veterans Affairs to improve access to cancer care for U.S. veterans.

  • June 28- Healthcare services provider McKesson Corp said it would combine most of its information technology business with Change Healthcare Holdings Inc to form a new company with combined pro forma annual revenue of $3.4 billion. Change Healthcare, a provider of software and analytics, network solutions and technology-enabled services, will contribute...

  • June 28- Healthcare services provider McKesson Corp said it would combine most of its information technology business with Change Healthcare Holdings Inc to form a new company with combined pro forma annual revenue of $3.4 billion. Change Healthcare, a provider of software and analytics, network solutions and technology-enabled services, will contribute...

  • *Offers $58/ share for HeartWare. June 27- Medtronic Plc said it would buy HeartWare International Inc for about $1.1 billion, bulking up its portfolio of devices for treating heart diseases and pushing deeper into the market for less-invasive surgical products. HeartWare shares rose as much as 92 pct to $57.58 in morning trading on Monday, just below the offer...

  • NEW YORK/ FRANKFURT, June 17- Bayer AG, the German chemicals and healthcare company trying to acquire Monsanto Co, is exploring a sale of its radiology supplies unit that could be worth more than $3 billion, according to people familiar with the matter. Its main products are Ultravist for computer tomography scans, with 318 million euros in sales in 2015, and...